Unit:
Speciality Infectious DiseasesLibrary of the School of Health Sciences
Supervisors info:
Ευάγγελος Γιαμαρέλλος- Μπουρμπούλης, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Αντώνιος Παπαδόπουλος, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Γεώργιος Δημόπουλος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Original Title:
Ανοσομεταβολές στη νόσο Covid-19 και ενδογενής χλωρίδα
Translated title:
Immunotransmission in Covid-19 disease and endogenous flora
Summary:
Coronaviruses are a diverse group of viruses that infect many different animals and can cause mild to severe respiratory infections in humans. At the end of 2019, a novel coronavirus defined as SARS-CoV-2 appeared in the city of Wuhan, China, and caused an epidemic of unusual viral pneumonia.
The role of the gut microbiome in the immune response and the progression of COVID-19 is documented by the available literature. The examination of probiotics for their effectiveness in the management of respiratory viral infections, combined with the increasingly obvious role of intestinal dysbiosis in the progression of the disease, includes this category of drugs in the possible treatment options.
A study was carried out in order to highlight the effect of probiotics on modifying the functionality of the immune system after mild COVID-19 disease. This is a prospective, double-blind, randomized one-to-one ratio, placebo-controlled study, in order to demonstrate the effectiveness of the oral probiotic administered in the optimal outcome of patients with mild COVID-19 disease.
The precursor results of the study demonstrate that improving the functionality of monocytes is associated with an improvement in the clinical outcome of patients with COVID-19 disease. The continuation and completion of the study will give more results with the aim of utilizing them in clinical practice.
Main subject category:
Health Sciences
Keywords:
Covid-19, Microbiota, Probiotics
